Cite
HARVARD Citation
Palomba, M. et al. (2021). Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. Leukemia & lymphoma. 62 (9), pp. 2169-2176. [Online].